...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes care >Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia.
【24h】

Atorvastatin and Micronized Fenofibrate Alone and in Combination in Type 2 Diabetes With Combined Hyperlipidemia.

机译：阿托伐他汀和微粉非诺贝特单独使用或合并2型糖尿病合并高脂血症的患者。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVE-This study evaluated the effect of a atorvastatin-fenofibrate combination on lipid profile, in comparison to each drug alone, in patients with type 2 diabetes and combined hyperlipidemia (CHL). RESEARCH DESIGN AND METHODS-A total of 120 consecutive patients, who were free of coronary artery disease (CAD) at entry, were studied for a period of 24 weeks. These patients were randomly assigned to atorvastatin (20 mg/day, n = 40), micronized fenofibrate (200 mg/day, n = 40), or a combination of both (atorvastatin 20 mg/day plus fenofibrate 200 mg/day, n = 40). The effect of treatment on LDL cholesterol, triglycerides (TGs), HDL cholesterol, apolipoprotein A-I and B, lipoprotein(a), and plasma fibrinogen (PF) was recorded. Moreover, the percentage of patients that reached the American Diabetes Association treatment goals and the estimated CAD risk status were calculated. RESULTS-No patient was withdrawn from the study because of side effects. The atorvastatin-fenofibrate combination reduced total cholesterol by 37%, LDL cholesterol by 46%, TGs by 50%, and PF by 20%, whereas it increased HDL cholesterol by 22% (P < 0.0001 for all). These changes were significantly better than those of both monotherapies. Of the patients on drug combination, 97.5% reached the LDL cholesterol treatment goal of <100 mg/dl, 100% reached the desirable TG levels of <200 mg/dl, and 60% reached the optimal HDL cholesterol levels of >45 mg/dl. These rates were significantly higher than those of both monotherapies. Combined treatment reduced the 10-year probability for myocardial infarction from 21.6 to 4.2%. CONCLUSIONS-The atorvastatin-fenofibrate combination has a highly beneficial effect on all lipid parameters and PF in patients with type 2 diabetes and CHL. It improved patients' CAD risk status significantly more than each drug alone.
机译：目的-这项研究评估了阿托伐他汀-非诺贝特联合治疗与2种糖尿病合并合并高脂血症（CHL）患者的每种药物相比对脂质分布的影响。研究设计和方法-入组120例无冠状动脉疾病（CAD）的连续患者，进行了为期24周的研究。这些患者被随机分配到阿托伐他汀（20 mg /天，n = 40），微粉非诺贝特（200 mg /天，n = 40），或两者的组合（阿托伐他汀20 mg /天，加上非诺贝特200 mg /天，n = 40）。记录了治疗对LDL胆固醇，甘油三酸酯（TGs），HDL胆固醇，载脂蛋白A-1和B，脂蛋白（a）和血浆纤维蛋白原（PF）的影响。此外，还计算了达到美国糖尿病协会治疗目标的患者百分比和估计的CAD风险状态。结果-没有患者因副作用而退出研究。阿托伐他汀-非诺贝特联合用药可使总胆固醇降低37％，LDL胆固醇降低46％，TGs降低50％，PF降低20％，而HDL胆固醇升高22％（所有P均<0.0001）。这些改变明显优于两种单一疗法。在接受药物联合治疗的患者中，有97.5％的患者达到了LDL胆固醇治疗目标<100 mg / dl，100％的患者达到了理想的TG水平<200 mg / dl，有60％的患者达到了最佳的HDL胆固醇水平> 45 mg / dl dl。这些比率显着高于两种单一疗法的比率。联合治疗将10年心肌梗塞的可能性从21.6％降低到4.2％。结论-阿托伐他汀-非诺贝特联合用药对2型糖尿病和CHL患者的所有血脂参数和PF具有高度有益的作用。与单独使用每种药物相比，它显着改善了患者的CAD风险状态。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号